Israel
OncoHost is a technology company based in Israel that is revolutionizing the field of precision medicine to enhance patient outcomes. The company's flagship product, PROphet®, utilizes a plasma-based, proteomic pattern analysis to deliver personalized treatment insights for non-small cell lung cancer (NSCLC) using just a single blood sample. This breakthrough offering provides valuable guidance to physicians in determining the most effective first-line immunotherapy treatment for each patient, significantly impacting overall survival.
Founded in 2017, OncoHost boasts an impressive leadership team comprised of seasoned entrepreneurs and industry experts. Additionally, the company has garnered substantial support, evidenced by its recent Series C investment of $35.00M on 10 May 2022, which was led by OurCrowd, Alive Israel HealthTech Fund, Leumi Partners, Menora Mivtachim, and Changer Club.
With a large-scale prospective clinical trial involving over 40 sites and 1,700 patients globally, OncoHost is well-positioned to pioneer the advancement of precision diagnostics and biomarker development to the next stage, making a notable impact within the biopharma, biotechnology, healthcare, and pharmaceutical industries.
